Total Payments
$167,323
2024 Payments
$19,182
Companies
15
Transactions
164
Medicare Patients
392
Medicare Billing
$63,924
Payment Breakdown by Category
Consulting$116,642 (69.7%)
Travel$35,887 (21.4%)
Research$10,451 (6.2%)
Food & Beverage$3,867 (2.3%)
Other$476.00 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $116,642 | 48 | 69.7% |
| Travel and Lodging | $35,887 | 47 | 21.4% |
| Unspecified | $10,451 | 8 | 6.2% |
| Food and Beverage | $3,867 | 60 | 2.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $476.00 | 1 | 0.3% |
Payments by Type
General
$156,872
156 transactions
Research
$10,451
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $48,180 | 48 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $30,827 | 38 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $17,969 | 14 | $0 (2024) |
| Gilead Sciences, Inc. | $16,420 | 4 | $0 (2023) |
| Kite Pharma, Inc. | $16,284 | 39 | $0 (2022) |
| F. Hoffmann-La Roche AG | $16,281 | 5 | $0 (2018) |
| Incyte Corporation | $4,053 | 3 | $0 (2022) |
| Eli Lilly and Company | $4,050 | 1 | $0 (2022) |
| Genentech USA, Inc. | $3,967 | 3 | $0 (2022) |
| Genentech, Inc. | $3,348 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,182 | 16 | Celgene Corporation ($9,989) |
| 2023 | $18,889 | 8 | Gilead Sciences, Inc. ($11,345) |
| 2022 | $21,067 | 11 | Gilead Sciences, Inc. ($5,075) |
| 2021 | $10,930 | 6 | Kite Pharma, Inc. ($3,780) |
| 2020 | $14,331 | 7 | Celgene Corporation ($8,750) |
| 2019 | $46,899 | 52 | Novartis Pharmaceuticals Corporation ($20,445) |
| 2018 | $27,463 | 45 | F. Hoffmann-La Roche AG ($16,281) |
| 2017 | $8,563 | 19 | Celgene Corporation ($8,376) |
All Payment Transactions
164 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $157.51 | General |
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $131.47 | General |
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $26.04 | General |
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $889.50 | General |
| 11/21/2024 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $444.75 | General |
| 11/14/2024 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $399.12 | General |
| 11/14/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $65.00 | General |
| 11/13/2024 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $346.69 | General |
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,558.00 | General |
| 07/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $103.82 | General |
| 06/11/2024 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $8,426.47 | General |
| 06/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,223.75 | General |
| 05/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $725.21 | General |
| 05/07/2024 | Celgene Corporation | ABECMA (Biological) | Food and Beverage | Cash or cash equivalent | $149.78 | General |
| Category: Oncology | ||||||
| 04/01/2024 | bluebird bio, Inc. | — | Food and Beverage | In-kind items and services | $51.90 | General |
| 01/31/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,482.50 | General |
| 12/20/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,310.00 | General |
| 09/28/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $296.50 | General |
| 07/06/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,965.00 | General |
| 03/29/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $444.75 | General |
| 02/08/2023 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,947.00 | General |
| 02/08/2023 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,298.00 | General |
| 02/01/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,034.59 | General |
| 01/23/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $593.00 | General |
| 12/22/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $3,710.00 | General |
| Category: CELLT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $6,961 | 6 |
| A study related to non-Hodgkin lymphoma, compares the efficacy of obinutizumab in combination with chemotherapy versus rituximab- based treatments for untreated advanced cases (CL-NHL-13648) | Celgene Corporation | $2,346 | 1 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001), A Phase 2 study of JCAR017 as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL & OUTREACH 3L+ LBCL 017007 (017001, 017006, 017007) | Celgene Corporation | $1,144 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 92 | 142 | $45,679 | $11,455 |
| 2022 | 2 | 100 | 197 | $64,484 | $18,960 |
| 2021 | 2 | 88 | 177 | $52,071 | $15,725 |
| 2020 | 4 | 112 | 220 | $82,904 | $17,783 |
Total Patients
392
Total Services
736
Medicare Billing
$63,924
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 48 | 87 | $23,060 | $5,872 | 25.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 40 | $19,636 | $4,794 | 24.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 15 | $2,984 | $789.74 | 26.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 52 | 84 | $38,972 | $10,510 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 113 | $25,512 | $8,450 | 33.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 55 | 123 | $27,476 | $9,451 | 34.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 33 | 54 | $24,595 | $6,274 | 25.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 46 | 125 | $53,193 | $11,409 | 21.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 41 | 67 | $19,603 | $4,307 | 22.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $7,156 | $1,392 | 19.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 14 | 17 | $2,953 | $675.45 | 22.9% |
About David Maloney
David Maloney is a Medical Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942385752.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Maloney has received a total of $167,323 in payments from pharmaceutical and medical device companies, with $19,182 received in 2024. These payments were reported across 164 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($116,642).
As a Medicare-enrolled provider, Maloney has provided services to 392 Medicare beneficiaries, totaling 736 services with total Medicare billing of $63,924. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Seattle, WA
- Active Since 10/27/2006
- Last Updated 01/25/2013
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1942385752
Products in Payments
- KYMRIAH (Biological) $29,101
- GAZYVA (Biological) $16,331
- Revlimid (Drug) $10,777
- JCAR017 (Drug) $8,318
- Yescarta (Drug) $6,610
- Abraxane (Drug) $4,714
- POLIVY (Biological) $3,800
- Non-Covered Product (Drug) $3,348
- Imbruvica (Drug) $1,567
- IMBRUVICA (Drug) $1,082
- ABECMA (Biological) $149.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Seattle
Bart Scott
Medical Oncology — Payments: $1.5M
Medical Oncology $1.5M
Petros Grivas, M.d, M.D
Medical Oncology — Payments: $683,103
Medical Oncology $683,103
Evan Yu
Medical Oncology — Payments: $356,321
Medical Oncology $356,321
Gary Lyman, Md, MD
Medical Oncology — Payments: $176,021
Medical Oncology $176,021
Jerald Radich, Md, MD
Medical Oncology — Payments: $171,817
Medical Oncology $171,817
Laura Chow, Md, MD
Medical Oncology — Payments: $156,359
Medical Oncology $156,359